Phaseline

Companies › Annovis Bio

Annovis Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
buntanetap–Phase 3Early Alzheimers Disease; Parkinson's Disease (PD)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06709014buntanetapPhase 3Early Alzheimers DiseaseNeurologyDec 2027
NCT07284784buntanetapPhase 2Parkinson's Disease (PD)NeurologySep 2029

From the company's SEC filings

Cash of $19m on 2026-06-30; operating cash outflow about $63m a year; runway about 4 months at that burn, to Oct 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biohaven Pharmaceuticals Larimar Therapeutics Immunic Alpha Cognition NervGen Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.